Testing for CHEK2 in the cancer genetics clinic: Ready for prime time?

Clinical Genetics

Volumn 78, Issue 1, 2010, Pages 1-7

  Narod, S A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Breast cancer; CHEK2

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CHECKPOINT KINASE 2; TAMOXIFEN; CHEK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; FAMILY HISTORY; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; LUNG CANCER; MISSENSE MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; BREAST NEOPLASMS; FEMALE; GENETICS; MASS SCREENING; MUTATION; PROCEDURES;

BREAST NEOPLASMS; CHECKPOINT KINASE 2; CHEMOPREVENTION; FEMALE; GENETIC TESTING; HUMANS; MAGNETIC RESONANCE IMAGING; MASS SCREENING; MUTATION; PROTEIN-SERINE-THREONINE KINASES; TAMOXIFEN;

EID: 77954579781     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2010.01402.x     Document Type: Review

References (61)

1. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004, 4:665-676.
2. Miki Y, Swensen J, Shattuck-Eidens D. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
3. Wooster R, Bignell G, Lancaster J. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
4. Seal S, Thompson D, Renwick A. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38:1239-1241.
5. Rahman N, Seal S, Thompson D. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39:165-167.
6. Gonzalez KD, Noltner KA, Buzin CH. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009, 27:1250-1256.
7. Easton DF, Pooley KA, Dunning AM. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
8. Meijers-Heijboer H, van den Ouweland A, Klijn J. Low-penetrance susceptibility to breast cancer due to CHEK2(*) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002, 31:55-59.
9. Weischer M, Bojesen SE, Tybjaerg-Hansen A. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 2007, 25:57-63.
10. De Jong MM, van der Graaf WTA, Nolte IM. Increased CHEK2 110delC genotype frequency in unselected breast cancer patients. J Clin Oncol 2004, 22((suppl)):844s.
11. Kleibl Z, Novotny J, Bezdickova D. The CHEK2 110delC mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat 2005, 90:165-167.
12. Rashid MU, Jakubowska A, Justenhoven C. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur J Cancer 2005, 18:2896-2903.
13. Offit K, Pierce H, Kirchoff T. Frequency of CHEK2* 1100delC in New York breast cancer cases and controls. BMC Med Genet 2003, 4:1.
14. CHEK2* 1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004, 74:1175-1182. CHEK2 Breast Cancer Case-Control Consortium
15. Vahteristo P, Bartkova J, Eerola H. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002, 71:432-438.
16. Weischer M, Bojeson SE, Ellervik C. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analysis of 26,000 patients cases and 27,000 controls. J Clin Oncol 2008, 26:542-548.
17. Bell DW, Kim SH, Godwin AK. Genetic and functional analysis of CHEK2 variants in multi-ethic cohorts. Int J Cancer 2007, 121:2661-2667.
18. Thompson D, Seal S, Schutte M. A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev 2006, 15:2542-2545.
19. Ghadirian P, Robidoux A, Zhang P. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet 2009, 76:421-426.
20. Zhang S, Phelan CM, Zhang P. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. Cancer Res 2008, 68:2154-2157.
21. Cybulski C, Wokolorczyk D, Huzarski T. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat 2007, 102:119-122.
22. Osorio A, Rodriguez-Lopez R, Diez O. The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population. Int J Cancer 2004, 108:54-56.
23. Caligo MA, Agata S, Aceto G. The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum Mutat 2004, 24:100-101.
24. Lee AS. Ang P.CHEK2*1100delC screening of Asian women with a family history of breast cancer is unwarranted. J Clin Oncol 2008, 10((26)):2419.
25. Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 2005, 116:263-266.
26. Bogdanova N, Feshchenko S, Cybulski C, Dörk T. CHEK2 mutation and hereditary breast cancer. J Clin Oncol 2007, 25:e26.
27. Sokolenko AP, Rozanov ME, Mitiushkina NV. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer 2007, 6:281-286.
28. Walsh T, Casadei S, Coats KH. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295:1379-1388.
29. Dong X, Wang L, Taniguchi K. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003, 72:270-280.
30. Seppala EH, Ikonen T, Mononen N. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003, 89:1966-1970.
31. Cybulski C, Wokolocrzyk D, Huzarski T. A large germline deletion in the chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 2006, 43:863-866.
32. Cybulski C, Gorski B, Huzarski T. CHEK2 is a multi-organ cancer susceptibility gene. Am J Hum Genet 2004, 75:1131-1135.
33. Meijers-Heijboer H, Wijnen J, Vasen H. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003, 72:1308-1314.
34. Djureinovic T, Lindblom A, Dalén J. The CHEK2 1100delC variant in Swedish colorectal cancer. Anticancer Res 2006, 26:4885-4888.
35. Naseem H, Boylan J, Speake D. Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes. Clin Genet 2006, 70:388-395.
36. Sánchez de Abajo A, de la Hoya M, Godino J. The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families. Fam Cancer 2005, 4:183-186.
37. Kilpivaara O, Laiho P, Aaltonen LA, Nevanlinna H. CHEK2 1100delC and colorectal cancer. J Med Genet 2003, 40:e110.
38. Kilpivaara O, Vahteristo P, Falck J. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004, 111:543-547.
39. Cybulski C, Wokołorczyk D, Kładny J. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet 2007, 15:237-241.
40. Kleibl Z, Havranek O, Hlavata I. The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer 2009, 45:618-624.
41. Szymanska-Pasternak J, Szymanska A, Medrek K. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 2006, 102:429-431.
42. Brennan P, McKay J, Moore L. Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study. Hum Mol Genet 2007, 16:1794-1801.
43. Cybulski C, Masojc B, Oszutowska D. Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis 2008, 29:762-765.
44. Metcalfe K, Lubinski J, Lynch H. Family history of cancer and the risk of cancer in women with a BRCA1 or BRCA2 mutation. (In press).
45. Gronwald J, Cybulski C, Piesiak W. Cancer risks in first-degree relatives of CHEK2 mutation carriers: effect of mutation type and cancer site in proband. Br J Cancer 2009, 100:1508-1512.
46. Johnson N, Fletcher O, Naceur-Lombardelli C. Interaction between CHEK2*delC and other low-pentrance breast cancer susceptibility genes: a familial study. Lancet 2005, 366:1554-1557.
47. Oldenburg RA, Kroweze-Jansema K, Houwing JJ. The CHEK2110 delC varient acts as a brest cancer risk modifier in non-BRCA1/BRCA2 multiple case families. Cancer Res 2003, 64:8153-8157.
48. Fletcher O, Johnson N, Dos Santos Silva I. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev 2009, 18:230-234.
49. Cybulski C, Górski B, Huzarski T. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. J Med Genet 2009, 46:132-135.
50. Serrano-Fernandez P, Debniak T, Gorski B. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk. Breast Cancer Res Treat 2009, 117:161-165.
51. Cybulski C, Gliniewicz B, Sikorski A. Epistatic relationship between the cancer susceptibility genes CHEK2 and p27. Cancer Epidemiol Biomarkers Prev 2007, 16:572-576.
52. Saslow D, Boetes C, Burke W. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57:75-89.
53. Fisher B, Costantino JP, Wickerham DL. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97:1652-1662.
54. de Bock GH, Mourits MJ, Schutte M. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status. Int J Gynecol Cancer 2006, 16((Suppl 2)):552-555.
55. Cybulski C, Huzarski T, Byrski T. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. Clin Genet 2009, 75:72-78.
56. Kilpivaara O, Bartkova J, Eerola J. Correlation of CHEK2 protein expression and 1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 2005, 113:575-580.
57. de Bock GH, Schutte M, Krol-Warmerdam EM. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 2004, 41:731-735.
58. Cybulski C, Górski B, Huzarski T. CHEK2-positive breast cancers in young Polish women. Clin Cancer Res 2006, 12:4832-4835.
59. Schmidt MK, Tollenaar RAEM, de Kemp SR. Breast cancer survival and tumor characteristics in pre-menopausal women carrying the CHEK2*1100delC mutation. J Clin Oncol 2007, 25:64-69.
60. Schröder FH, Hugosson J, Roobol MJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
61. Andriole GL, Crawford ED, Grubb RL. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.